Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
Kereiakes
Dean J
DJ
Lindner Center for Research & Education and Ohio Heart Health Center, Cincinnati, Ohio, USA. lindner@fuse.net
Lincoff
A Michael
AM
Anderson
Keaven M
KM
Achenbach
Robert
R
Patel
Kamlesh
K
Barnathan
Elliot
E
Califf
Robert M
RM
Topol
Eric J
EJ
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000401:mortality / Q000628:therapy*; D004311:Double-Blind Method; D023381:Endpoint Determination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab